US Broker Ratings

Amicus Therapeutics, Inc. (FOLD) Stock Analysis: A Biotech Powerhouse in Rare Diseases with Potential Upside

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is capturing the attention of the healthcare investment community with its strategic focus on rare diseases. Headquartered in Princeton, New Jersey,..

GeneDx Holdings Corp. (WGS) Investor Outlook: Potential 105.84% Upside Amid Strong Buy Ratings

GeneDx Holdings Corp. (NASDAQ: WGS) is making waves in the healthcare sector with its innovative approach to genetic testing services. The company, headquartered in Stamford, Connecticut,..

Progyny, Inc. (PGNY) Stock Analysis: A Promising Upside with 60.73% Potential Growth

For investors eyeing innovative healthcare solutions, Progyny, Inc. (NASDAQ: PGNY) presents an intriguing opportunity. Specializing in fertility and family-building benefits management, Progyny has carved out a..

Ligand Pharmaceuticals (LGND) Stock Analysis: A Biotech Gem with 17.66% Upside Potential

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has emerged as a compelling prospect in the biotech sector, boasting a market capitalization of $4.14 billion. This American biopharmaceutical company,..

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Strong Buy Ratings and 50% Upside Potential

For investors seeking opportunities in the biotechnology sector, Kymera Therapeutics, Inc. (NASDAQ: KYMR) offers a compelling prospect. This clinical-stage biopharmaceutical company is making strides with its..

IDEAYA Biosciences, Inc. (IDYA) Investor Outlook: Unpacking a 43.72% Potential Upside

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is capturing the attention of investors with its promising pipeline in precision medicine oncology. As of its latest trading session, the..

Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook with a Promising 25.80% Potential Upside

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a notable player in the biopharmaceutical sector, is gaining attention for its focus on developing innovative treatments for central nervous system..

GoodRx Holdings (GDRX) Stock Analysis: Navigating a 26.82% Potential Upside in the Healthcare Sector

Investors on the lookout for opportunities in the healthcare sector might find GoodRx Holdings, Inc. (NASDAQ: GDRX) an intriguing prospect. As a prominent player in Health..

Zai Lab Limited (ZLAB) Stock Analysis: Potential 105% Upside Awaits Investors

As the biotechnology sector continues its relentless pursuit of groundbreaking medical solutions, Zai Lab Limited (ZLAB), a prominent player in the field, emerges as a notable..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Unveiling a 31% Upside Potential in the Biotech Sector

For investors with a keen eye on the biotechnology sector, PTC Therapeutics, Inc. (NASDAQ: PTCT) presents an intriguing opportunity with a potential upside of 31.27%. With..

PACS Group, Inc. (PACS) Stock Analysis: Unpacking a 32% Potential Upside in the Healthcare Sector

PACS Group, Inc. (PACS) is making waves in the healthcare sector with its compelling financial metrics and positive analyst outlook. This Salt Lake City-based company, founded..

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: Exploring a 15.30% Potential Upside in the Growing Medical Devices Market

PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a pioneering entity in the healthcare sector, specifically within the medical devices industry, is making waves with its significant market presence..

HUTCHMED (China) Limited (HCM) Stock Analysis: Exploring a 50% Upside Potential in the Healthcare Sector

HUTCHMED (China) Limited (HCM), a prominent player in the healthcare sector, is making waves with its innovative approach to cancer and immunological disease treatments. Headquartered in..

QuidelOrtho Corporation (QDEL) Stock Analysis: Unveiling a 96% Potential Upside in Healthcare Diagnostics

QuidelOrtho Corporation (NASDAQ: QDEL), a prominent player in the healthcare sector, is capturing the attention of investors with its formidable presence in the medical devices industry...

Kiniksa Pharmaceuticals Interna (KNSA) Stock Analysis: A Promising 23.39% Upside with Robust Revenue Growth

Kiniksa Pharmaceuticals Interna (NASDAQ: KNSA), a prominent player in the specialty and generic drug manufacturing industry, has recently caught the eye of investors with its compelling..

Enovis Corporation (ENOV) Stock Analysis: Exploring a 94.67% Potential Upside for Investors

Enovis Corporation (NYSE: ENOV), a player in the healthcare sector, focuses on delivering innovative medical device solutions that cater to both the Prevention and Recovery and..

Concentra Group Holdings Parent (CON): Investor Outlook Reveals 28% Upside Potential

Concentra Group Holdings Parent (NASDAQ: CON), a prominent player in the healthcare sector, specifically in medical care facilities, is catching the attention of individual investors with..

Phreesia, Inc. (PHR) Stock Analysis: A 155% Potential Upside Opportunity Amid Healthcare Innovation

Phreesia, Inc. (NYSE: PHR), a prominent player in the health information services industry, has caught the attention of investors with a substantial potential upside of 155.26%...

Mirum Pharmaceuticals (MIRM) Stock Analysis: A Biotech Powerhouse with 34.54% Upside Potential

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is carving out a distinctive niche in the biotechnology sector, focusing on developing and commercializing treatments for rare and orphan diseases...

CG Oncology, Inc. (CGON) Stock Analysis: Strong Buy Ratings and a Promising 22.81% Upside Potential

In the dynamic landscape of biotechnology, CG Oncology, Inc. (NASDAQ: CGON) emerges as a formidable player with its innovative approach to cancer treatment. Specializing in the..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds